NPG-2044 is under clinical development by Novita Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NPG-2044’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NPG-2044 is under development for the treatment of solid tumors including ovarian cancer, endometrial cancer, uterine cancer, fallopian tube cancer, cervical cancer, vulvar cancer, vaginal cancer and triple-negative breast cancer. It is a small molecule administered through oral route. It acts by targeting fascin protien. It is a new molecular entity (NME).
It was under development for the treatment of colon cancer, esophageal cancer, lymphoma, metastatic breast cancer, metastatic pancreatic cancer, metastatic prostate cancer, metastatic lung cancer, metastatic liver cancer, metastatic ovarian cancer.
Novita Pharmaceuticals overview
Novita Pharmaceuticals, is a developer of therapeutic drugs for the treatment of cancer. The company is headquartered in United States.
For a complete picture of NPG-2044’s drug-specific PTSR and LoA scores, buy the report here.